CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
Our 12-month price target remains $67, 26x our 2026 EPS estimate (raised by $0.09 to $2.58; 2027 estimate raised by $0.06 to $3.05), below DXCM's one-year historical forward average of 33.5x and well below long-term term historical averages to reflect stronger competition within the continuous glucose monitoring space and uncertain insurance coverage and rebate dynamics, in our view. On May 14, DXCM announced a collaboration with activist investment firm Elliott Management, which holds a meaningful equity stake in DCXM (undisclosed amount), based on DXCM's recent press release. Among other potential changes, DXCM is making changes to the composition of its Board of Directors. The company also revealed some details about the upcoming G8 device, which is 50% smaller than the G7 and offers superior performance in terms of speed and real-time sensing capabilities. The G8 is expected to launch toward the end of 2027 or beginning of 2028.